Extending the Lipidome Coverage by Combining Different Mass Spectrometric Platforms: An Innovative Strategy to Answer Chemical Food Safety Issues.
Jérémy MarchandYann GuittonEstelle MartineauAnne-Lise RoyerDavid BalgomaAbdoulaye Zié KonéPatrick GiraudeauGaud DervillyPublished in: Foods (Basel, Switzerland) (2021)
From a general public health perspective, a strategy combining non-targeted and targeted lipidomics MS-based approaches is proposed to identify disrupted patterns in serum lipidome upon growth promoter treatment in pigs. Evaluating the relative contributions of the platforms involved, the study aims at investigating the potential of innovative analytical approaches to highlight potential chemical food safety threats. Serum samples collected during an animal experiment involving control and treated pigs, whose food had been supplemented with ractopamine, were extracted and characterised using three MS strategies: Non-targeted RP LC-HRMS; the targeted Lipidyzer™ platform (differential ion mobility associated with shotgun lipidomics) and a homemade LC-HRMS triglyceride platform. The strategy enabled highlighting specific lipid profile patterns involving various lipid classes, mainly in relation to cholesterol esters, sphingomyelins, lactosylceramide, phosphatidylcholines and triglycerides. Thanks to the combination of non-targeted and targeted MS approaches, various compartments of the pig serum lipidome could be explored, including commonly characterised lipids (Lipidyzer™), triglyceride isomers (Triglyceride platform) and unique lipid features (non-targeted LC-HRMS). Thanks to their respective characteristics, the complementarity of the three tools could be demonstrated for public health purposes, with enhanced coverage, level of characterization and applicability.
Keyphrases
- public health
- cancer therapy
- mass spectrometry
- multiple sclerosis
- ms ms
- high throughput
- dna methylation
- gene expression
- drug delivery
- healthcare
- simultaneous determination
- high resolution mass spectrometry
- fatty acid
- high resolution
- single cell
- replacement therapy
- health insurance
- affordable care act
- combination therapy
- newly diagnosed
- high density